Company profile for LeonaBio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

LeonaBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases with significant unmet medical needs. The company is advancing a pipeline of novel small-molecule therapeutics targeting treatment-resistant metastatic breast cancer and neurodegenerative conditions such as ALS. With a strong emphasis on scientific innovation and patient-centered research, LeonaBio aims to develop tra...
LeonaBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases with significant unmet medical needs. The company is advancing a pipeline of novel small-molecule therapeutics targeting treatment-resistant metastatic breast cancer and neurodegenerative conditions such as ALS. With a strong emphasis on scientific innovation and patient-centered research, LeonaBio aims to develop transformative therapies that improve patient outcomes and address critical healthcare challenges globally

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
18706 North Creek Parkway Suite 104 Bothell, WA 98011
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

PEGS Boston Summit

PEGS Boston Summit

Not Confirmed

envelop Contact Supplier

PEGS Boston Summit

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Athira Pharma Rebrands To Leonabio
Athira Pharma Rebrands To Leonabio

09 Jan 2026

// FIERCE PHARMA

https://www.fiercepharma.com/marketing/athira-pharma-roars-new-year-rebrand-leonabio

FIERCE PHARMA
09 Jan 2026

https://www.globenewswire.com/news-release/2025/12/18/3207578/0/en/Athira-Pharma-Announces-Exclusive-License-to-Lasofoxifene-Phase-3-Development-Program-for-Metastatic-Breast-Cancer-Candidate-and-a-Financing-for-up-to-236-Million.html

GLOBENEWSWIRE
18 Dec 2025

https://www.globenewswire.com/news-release/2025/11/06/3183110/0/en/Athira-Pharma-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
06 Nov 2025

https://www.globenewswire.com/news-release/2025/09/11/3148572/0/en/Athira-Pharma-Announces-Reverse-Stock-Split.html

GLOBENEWSWIRE
11 Sep 2025

https://www.globenewswire.com/news-release/2025/08/14/3133303/0/en/Athira-Pharma-Presents-ATH-1105-Phase-1-Trial-Results-at-ALS-Nexus-2025.html

GLOBENEWSWIRE
14 Aug 2025

https://www.globenewswire.com/news-release/2025/08/07/3129673/0/en/Athira-Pharma-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
07 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty